A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.

A mutation scoring system was conducted based on the number of mutations and a unique favorable prognostic factor. MIPSS-R, the novel integral risk stratification system was developed by integrating IPSS-R and the mutation scores, which is more effective on prognosis and treatment guidance for MDS patients.